Summary Primatene Mist inhalers provide temporary relief from mild, intermittent asthma symptoms. They are the only OTC ...

The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST ®, Amphadase ®, Cortrosyn ®, REXTOVY ® and ...

Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, ...

Dan Dischner; Vice President - Corporate Communications; Amphastar Pharmaceuticals Inc. William Peters; Chief Financial Officer, Executive Vice President - Finance, ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

If currently taking a prescription monoamine oxidase inhibitor (MAOI) (eg, certain drugs taken for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after ...

Amphastar Pharmaceuticals Inc ( (AMPH) ) has released its Q3 earnings. Here is a breakdown of the information Amphastar Pharmaceuticals Inc ...

Amphastar Pharmaceuticals Inc (AMPH) reports a 6% revenue increase, driven by record Primatene Mist sales, despite facing competitive and logistical hurdles.

A key highlight for the quarter was Primatene Mist, which achieved its highest quarterly sales since the launch, reaching $26 million in sales. This performance is a significant step toward our ...

The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.